基因工程毒素 (DAB486IL-2) 对慢性淋巴细胞白血病患者的治疗效果
C F LeMaistre1, M G Rosenblum, J M Reuben
1Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio 78284-7880.
Lancet (London, England)
|May 11, 1991
概括
DAB486IL-2是一种融合蛋白,向具有高亲和IL-2受体的癌细胞. 一名耐其他治疗方法的慢性淋巴细胞白血病患者对这种新疗法产生了积极反应.
科学领域:
- 生物技术是生物技术.
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 双菌毒素是一种强大的细胞毒素.
- 干白素-2 (IL-2) 受体在某些白血病细胞上具有高度表达.
- 向性癌症疗法旨在选择性地消除恶性细胞.
更多相关视频
08:17A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
Published on: August 15, 2019
08:05Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...